Please provide your email address to receive an email when new articles are posted on . The phase 2 study of ALTO-203 will involve about 60 adults with MDD and evidence of anhedonia. ALTO-203 has ...

LOS ALTOS, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced the initiation of a Phase 2 double-blind, placebo-controlled study of its transdermal formulation of ...

Alto Neuroscience’s phase 2 depression trial has missed its primary efficacy endpoint, as patients on the drug candidate fared no better on a measure of alertness and mood than their peers on placebo.

Another of Alto Neurosciences’ machine learning-derived, biomarker-based depression therapies has improved symptoms, boosting the case for the biotech’s precision psychiatry approach. ALTO-300 was ...

– Topline data for Phase 2 trials of ALTO-101 in CIAS expected 1Q 2026 and ALTO-300 in MDD expected mid-2026 – – Closed $50 million PIPE; strong cash position of $184.2 million as of October 31 ...